6-Thioguanine therapy in Crohn′s disease-Observational data in Swedish patients

Digestive and Liver Disease

Volumn 41, Issue 3, 2009, Pages 194-200

  Almer, S H C ^a   Hjortswang, H ^a   Hindorf, U ^b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Faculty of Medicine   (Sweden)

Author keywords

6 thioguanine; Drug toxicity; Inflammatory bowel disease; Thiopurine drugs

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TIOGUANINE;

ADULT; AGED; ARTICLE; BLEEDING; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLON RESECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DATA ANALYSIS; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE COUNT; FATTY LIVER; FEMALE; GALLSTONE; GASTROINTESTINAL TOXICITY; HEART FUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER FIBROSIS; LIVER HYPERPLASIA; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MALE; NEUROTOXICITY; OBSERVATIONAL STUDY; PAIN; PANCREATITIS; PORTAL HYPERTENSION; PROSPECTIVE STUDY; REMISSION; SIDE EFFECT; SPLENOMEGALY; SWEDEN; TREATMENT DURATION;

6-MERCAPTOPURINE; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AZATHIOPRINE; CROHN DISEASE; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SWEDEN; THIOGUANINE; YOUNG ADULT;

EID: 60649106530     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2008.07.314     Document Type: Article

References (29)

1. Dubinsky M.C., Hassard P.V., Seidman E.G., Kam L.Y., Abreu M.T., Targan S.R., et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 7 3 (2001) 181-189
2. Bonaz B., Boitard J., Marteau P., Lemann M., Coffin B., Flourie B., et al. Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 18 4 (2003) 401-408
3. Derijks L.J., de Jong D.J., Gilissen L.P., Engels L.G.J.B., Hooymans P.M., Jansen J.B.M.J., et al. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur J Gastroenterol Hepatol 15 1 (2003) 63-67
4. Dubinsky M.C., Feldman E.J., Abreu M.T., Targan S.R., and Vasiliauskas E.A. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol 98 5 (2003) 1058-1063
5. Herrlinger K.R., Kreisel W., Schwab M., Schoelmerich J., Fleig W.E., Ruhl A., et al. 6-thioguanine-efficacy and safety in chronic active Crohn's disease. Aliment Pharmacol Ther 17 4 (2003) 503-508
6. Teml A., Schwab M., Harrer M., Miehsler W., Schaeffeler E., Dejaco C., et al. A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis. Scand J Gastroenterol 40 10 (2005) 1205-1213
7. de Boer N.K., Derijks L.J., Gilissen L.P.L., Hommes D.W., Engels L.G.J.B., de Boer S.Y., et al. On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients. World J Gastroenterol 11 35 (2005) 5540-5544
8. Qasim A., McDonald S., Sebastian S., McLoughlin R., Buckley M., O'Connor H., et al. Efficacy and safety of 6-thioguanine in the management of inflammatory bowel disease. Scand J Gastroenterol 42 (2007) 194-199
9. de Jong D., Mulder C.J., and van Sorge A.A. Why measure thiopurine methyltransferase activity? Direct administration of 6-thioguanine might be the alternative for 6-mercaptopurine or azathioprine. Gut 49 6 (2001) 874
10. Cheung T.K., and Florin T.H. 6-thioguanine: a new old drug to procure remission in inflammatory bowel disease. Int Med J 33 1, 2 (2003) 44-46
11. Herrlinger K.R., Fellermann K., Fischer C., Kresisel W., Deibert P., Schoelmerich J., et al. Thioguanine-nucleotides do not predict efficacy of tioguanine in Crohn's disease. Aliment Pharmacol Ther 19 (2004) 1269-1276
12. Derijks L.J., Gilissen L.P., Engels L.G., Bos L.P., Bus P.J., Lohman J.J.H.M., et al. Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease. Ther Drug Monit 28 (2006) 45-50
13. Dubinsky M.C., Vasiliauskas E.A., Singh H., Abreu M.T., Papadakis K.A., Tran T., et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 125 (2003) 298-303
14. Geller S.A., Dubinsky M.C., Poordad F.F., Vasiliauskas E.A., Cohen A.H., Abreu M.T., et al. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol 28 9 (2004) 1204-1211
15. Shastri S., Dubinsky M.C., Poordad F., Vasiliauskas E.A., and Geller S.A. Early nodular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thioguanine therapy. Arch Pathol Lab Med 128 1 (2004) 49-53
16. Seiderer J., Zech C.J., Reinisch W., Lukas M., Diebold J., Wrba F., et al. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol 43 2 (2005) 303-309
17. de Boer N.K.H., Zondervan P.E., Gilissen L.P.L., den Hartog G., Westerveld B.D., Derijks L.J.J., et al. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients. Dig Liver Dis 40 (2008) 108-113
18. Ferlitsch A., Teml A., Reinisch W., Ulbrich G., Wrba F., Homoncik M., et al. 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension. Am J Gastroenerol 102 (2007) 2495-2503
19. Fritz E., Wrba F., and Knoflach P. Variceal hemorrhage in a patient with ulcerative colitis treated with 6-thioguanine. Infl Bowel Dis 14 (2008) 582-583
20. de Boer N.K., Reinisch W., Teml A., van Bodegraven A.A., Schwab M., Lukas M., et al. 6-Thioguanine (6-TG) treatment in inflammatory bowel disease: a critical appraisal by an European 6-TG working party. Digestion 73 (2006) 25-31
21. Harvey R., and Bradshaw M. A simple index of Crohn's disease activity. Lancet 1 (1980) 514
22. Pettersson B., Almer S., Albertioni F., Söderhäll S., and Peterson C. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate. Ther Drug Monit 24 (2002) 351-358
23. Haglund S., Lindqvist M., Almer S., Peterson C., and Taipalensuu J. Pyrosequencing of TPMT alleles in a general Swedish population and in patients with inflammatory bowel disease. Clin Chem 50 2 (2004) 288-295
24. Gilissen L.P.L., Derijks L.J.J., Driessen A., Bos L.P., Hooymans P.M., Stockbrugger R.W., et al. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD-patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?. Dig Liver Dis 39 (2007) 156-159
25. Hindorf U., Lindqvist M., Hildebrand H., Fagerberg U., and Almer S. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther 24 2 (2006) 331-342
26. Boulton-Jones J.R., Pritchard K., and Mahmoud A.A. The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment Pharmacol Ther 14 12 (2000) 1561-1565
27. Bowen D.G., and Selby W.S. Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine. Dig Dis Sci 45 9 (2000) 1810-1813
28. Domenech E., Nos P., Papo M., Lopez-San Roman A., Garcia-Planella E., and Gassull M.A. 6-mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine. Scand J Gastroenterol 40 1 (2005) 52-55
29. Teml A., Schwab M., Hommes D., Almer S., Lukas M., Feichtenschlager T., et al. A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease. Wien Klin Wochenschr 119 (2007) 519-526